ReviewIntensive care medicine2016
Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum.
Review in Intensive care medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03549923 (Impact of Early CRRT Intervention in Patients Receiving VA-ECMO Support on 30-day Mortality), which is not on this map. Cited by 93 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Early CRRT Intervention in Patients Receiving VA-ECMO Support on 30-day Mortality: A Randomized Controlled Trial
Who cites it
93 citing papers in PubMed, 4 syntheses or guidelines pooled it, 169 citations in OpenAlex.
- Mortality effect of higher versus lower blood pressure targets in vasodilatory shock: an updated systematic review and meta-analysis.Critical care (London, England) · 2025Pooled it
- Ivabradine use in critical care: a systematic review and metanalysis of cardiogenic and septic shock patients.BMC anesthesiology · 2025Pooled it
- Clinical Efficiency of Vasopressin or Its Analogs in Comparison With Catecholamines Alone on Patients With Septic Shock: A Systematic Review and Meta-Analysis.Frontiers in pharmacology · 2020Pooled it
- Pooled analysis of higher versus lower blood pressure targets for vasopressor therapy septic and vasodilatory shock.Intensive care medicine · 2018Pooled it
- Twenty percent human albumin solution fluid bolus administration therapy in patients after cardiac surgery-II: a multicentre randomised controlled trial.Intensive care medicine · 2024Trial
- Levosimendan in septic shock in patients with biochemical evidence of cardiac dysfunction: a subgroup analysis of the LeoPARDS randomised trial.Intensive care medicine · 2019Trial
- Microcirculation improvement after short-term infusion of vasopressin in septic shock is dependent on noradrenaline.Clinics (Sao Paulo, Brazil) · 2017Trial
- State-of-the-art review: ß-blockade in critical illness.Intensive care medicine · 2026Review
- [Vasopressors in septic shock: the old and the new].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2026Review
- Nanopore-enabled time-resolved monitoring of catecholamine-related phenylalanine metabolism.Nature nanotechnology · 2026Article
- Addressing metabolic demands during veno-venous extracorporeal life support: A narrative review.JPEN. Journal of parenteral and enteral nutrition · 2026Review
- Current and future strategies aiming at reducing catecholamine exposure in septic shock.Critical care (London, England) · 2026Review
- Effects of septic shock vasopressors on the fitness of Escherichia coli.Scientific reports · 2026Article
- Managing sepsis in the era of precision medicine: a narrative review.Acute and critical care · 2026Article
- Five things the intensivist cannot forget in the management of septic shock.Critical care science · 2026Article
- Ketamine, Etomidate, and Mortality in Emergency Department Intubations.JAMA network open · 2025Observational
- Norepinephrine exacerbates LPS-induced cardiomyopathy via SIRT3/HO-1 axis-mediated ferroptosis.Critical care (London, England) · 2025Article
- Latest updates on pathogenesis mechanisms and management strategies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis related to CAR-T cell therapies.Annals of hematology · 2025Review
- Observational
- Catecholamines in sepsis: pharmacological insights and clinical applications-a narrative review.Journal of anesthesia, analgesia and critical care · 2025Review
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catecholamines are endogenous neurosignalling mediators and hormones. They are integral in maintaining homeostasis by promptly responding to any stressor. Their synthetic equivalents are the current mainstay of treatment in shock states to counteract myocardial depression and/or vasoplegia. These phenomena are related in large part to decreased adrenoreceptor sensitivity and altered adrenergic signalling, with resultant vascular and cardiomyocyte hyporeactivity. Catecholamines are predominantly used in supraphysiological doses to overcome these pathological consequences. However, these adrenergic agents cause direct organ damage and have multiple 'off-target' biological effects on immune, metabolic and coagulation pathways, most of which are not monitored or recognised at the bedside. Such detrimental consequences may contribute negatively to patient outcomes. This review explores the schizophrenic 'Jekyll-and-Hyde' characteristics of catecholamines in critical illness, as they are both necessary for survival yet detrimental in excess. This article covers catecholamine physiology, the pleiotropic effects of catecholamines on various body systems and pathways, and potential alternatives for haemodynamic support and adrenergic modulation in the critically ill.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.